The fracture risk assessment tool (FRAX®): Applications in clinical practice

Journal of Women's Health

Volumn 20, Issue 4, 2011, Pages 525-531

  Watts, Nelson B ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE DENSITY; BONE MASS; CLINICAL PRACTICE; COMPUTER PROGRAM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FRACTURE RISK ASSESSMENT TOOL; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

AGED; ALGORITHMS; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; INTERNET; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 79954556653     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2010.2294     Document Type: Article

References (47)

1. North American Menopause Society. Management of oste-oporosis in postmenopausal women: 2006 position state-ment of The North American Menopause Society. Menopause 2006;13:340-367.
2. National Osteoporosis Foundation. America's bone health: The state of osteoporosis and low bone mass in our nation. Washington DC: National Osteoporosis Foundation 2002.
3. U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon Gen-eral, 2004.
4. National Osteoporosis Foundation. Clinician's guide to pre-vention and treatment of osteoporosis. Available at www. nof.org/professionals/clinical- guidelines Accessed March 1, 2011.
5. Nguyen TV, Center JR, Eisman JA. Osteoporosis: Un-derrated, underdiagnosed and undertreated. Med J Aust 2004;180:S18-S22.
6. Delmas PD, van de Langerijt L, Watts NB, et al. Under-diagnosis of vertebral fractures is a worldwide problem: The IMPACT study. J Bone Miner Res 2005;20:557-563. (Pubitemid 40393062)
7. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: A nationwide study from Den-mark. Osteoporos Int 2005;16:134-141. (Pubitemid 40193199)
8. Kamel HK. Secondary prevention of hip fractures among the hospitalized elderly: Are we doing enough? J Clin Rheu-matol 2005;11:68-71. (Pubitemid 40577949)
9. Iba K, Takada J, Hatakeyama N, et al. Underutilization of antiosteoporotic drugs by orthopedic surgeons for preven-tion of a secondary osteoporotic fracture. J Orthop Sci 2006; 11:446-449. (Pubitemid 44496650)
10. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the U.K. Osteoporos Int 2008;19:385-397.
11. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX® and its applications to clinical prac-tice. Bone 2009;44:734-743.
12. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Os-teoporos Int 2007;18:1033-1046. (Pubitemid 47020000)
13. Silverman SL. Selecting patients for osteoporosis therapy. Ann NY Acad Sci 2007;1117:264-272. (Pubitemid 350191279)
14. Fardellone P. Predicting the fracture risk in 2008. Joint Bone Spine 2008;75:661-664.
15. Roux C, Thomas T. Optimal use of FRAX. Joint Bone Spine 2009;76:1-3.
16. Watts NB, Ettinger B, LeBoff MS. FRAX facts. J Bone Miner Res 2009;24:975-979.
17. Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366-375.
18. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: Implications for risk assessment. J Bone Miner Res 2002; 17:1237-1244. (Pubitemid 34680500)
19. de Villiers TJ. Bone health and osteoporosis in postmeno-pausal women. Best Pract Res Clin Obstet Gynaecol 2009;23:73-85.
20. Borgstrom F, Kanis JA. Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:885-900.
21. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX\Assessment and intervention thresholds for the U.K. Osteoporos Int 2008;19:1395-1408.
22. Dawson-Hughes B, Tosteson ANA, Melton LJ III, et al. Im-plications of absolute fracture risk assessment for osteopo-rosis practice guidelines in the USA. Osteoporos Int 2008;19: 449-458.
23. Tosteson AN, Melton LJ III, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 2008;19:437-447.
24. National Osteoporosis Foundation, International Society for Clinical Densitometry. National Osteoporosis Foundation/International Society for Clinical Densitometry (ISCD) FRAX implementation guide. Available at www.iscd.org/visitors/pdfs/FRAXImplementationGuide-000.pdf Accessed March 1, 2011.
25. National Osteoporosis Foundation. FRAX® implementation guide released to DXA manufacturers. September 22, 2009. Available at www.nof.org/news/2009- 0922-NOFNews Ac-cessed March 1, 2011.
26. Watts NB, Siris ES, Cummings SR, Bauer DC. Filtering FRAX. Osteoporos Int 2010;21:537-541.
27. McCloskey EV, Johansson H, Oden A, et al. Ten-year frac-ture probability identifies women who will benefit from clodronate therapy\Additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009; 20:811-817.
28. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedox-ifene reduces vertebral and clinical fractures in postmeno-pausal women at high risk assessed with FRAX. Bone 2009;44:1049-1054.
29. McCloskey E, Johansson H, Oden A, Chines A, Kanis J. Assessment of the effect of bazedoxifene on non-vertebral fracture risk. J Bone Miner Res 2009;24 (Suppl 1). Available at www.asbmr.org/Meetings/AnnualMeeting/Abstract Detail.aspx?aid = 6c55b263-692e-4a37-b807-f7a153641564 Ac-cessed October 18, 2010.
30. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and ver-tebral fractures and its dependency on FRAX. Bone 2010;47: 729-735.
31. Donaldson MG, Palermo L, Schousboe JT, Ensrud KE, Hochberg MC, Cummings SR FRAX and risk of vertebral fractures: The fracture intervention trial. J Bone Miner Res 2009;24:1793-1799.
32. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteo-porosis. Arthritis Care Res 2010;62:1515-1526.
33. Lewiecki EM, Watts NB. New guidelines for the prevention and treatment of osteoporosis. South Med J 2009;102:175-179.
34. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxf) 2000;39:1383-1389. (Pubitemid 32045866)
35. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-742. (Pubitemid 40933589)
36. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: A meta-analysis. Osteoporos Int 2005;16:155-162. (Pubitemid 40193202)
37. Delmas PD, Genant HK, Crans GG, et al. Severity of prev-alent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone 2003;33:522-532. (Pubitemid 37222378)
38. Lunt M, O'Neill TW, Felsenberg D, et al. Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: Results from the European Prospective Osteo-porosis Study (EPOS). Bone 2003;33:505-513. (Pubitemid 37222376)
39. Nanes MS, Kallen CB. Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. Fertil Steril 2009;92:403-412.
40. Watts NB, Lewiecki EM, Miller PD, Baim S. National Os-teoporosis Foundation 2008 clinician's guide to prevention and treatment of osteoporosis and the World Health Orga-nization Fracture Risk Assessment Tool (FRAX): What they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008;11:473-477.
41. Ettinger B. A personal perspective on fracture risk assess-ment tools. Menopause 2008;15:1023-1026.
42. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Os-teoporos Int 2001;12:519-528. (Pubitemid 32777427)
43. Robbins J, Aragaki AK, Kooperberg C, et al. Factors asso-ciated with 5-year risk of hip fracture in postmenopausal women. JAMA 2007;298:2389-2398. (Pubitemid 350190780)
44. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. De-velopment of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008;19:1431-1444.
45. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: Pro-spective derivation and validation of QFractureScores. BMJ 2009;339:b4229.
46. van den Bergh JP, van Geel TA, Lems WF, Geusens PP. Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 2010;8:131-137.
47. Binkley N, Lewiecki EM. The evolution of fracture risk es-timation. J Bone Miner Res 2010;25:2098-2100.